​

Spero Therapeutics (SPRO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SPRO Stock Rating

Spero Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (66.67%), 3 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 3 6 0 Strong Sell Sell Hold Buy Strong Buy

SPRO Price Target Upside V Benchmarks

TypeNameUpside
StockSpero Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.89$2.89$2.89
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 251-2--3
May, 251-2--3
Apr, 251-2--3
Mar, 251-2--3
Feb, 251-2--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024H.C. WainwrightBuyBuyhold
Nov 18, 2024Cowen & Co.BuyHolddowngrade
Oct 03, 2024H.C. WainwrightBuyBuyhold
Aug 06, 2024Cowen & Co.Buyupgrade
Sep 22, 2022Evercore ISIOutperformupgrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.46$-2.96$-1.28$0.43$-1.27----
Avg Forecast$-3.47$-2.73$-1.97$-0.65$-0.92$-0.58$-0.51$-0.20$0.42
High Forecast$-3.46$-2.72$-1.86$-0.65$-0.90$-0.55$-0.51$-0.20$0.42
Low Forecast$-3.47$-2.73$-2.19$-0.65$-0.94$-0.62$-0.51$-0.20$0.42
Surprise %-0.29%8.42%-35.03%-166.15%38.04%----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.33M$18.26M$48.58M$96.73M$47.98M----
Avg Forecast$11.07M$19.96M$7.12M$48.90M$38.97M$30.00M$1.30M$32.50M$63.00M
High Forecast$11.09M$19.99M$7.74M$48.90M$38.97M$30.00M$1.30M$32.50M$63.00M
Low Forecast$11.06M$19.94M$6.80M$48.90M$38.97M$30.00M$1.30M$32.50M$63.00M
Surprise %-15.73%-8.55%582.03%97.82%23.12%----

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-77.52M$-91.30M$-48.03M$22.81M$-68.57M----
Avg Forecast$-183.72M$-144.40M$-104.39M$-34.18M$-48.75M$-30.91M$-27.02M$-10.60M$22.26M
High Forecast$-183.41M$-144.15M$-98.31M$-34.18M$-47.53M$-28.95M$-27.02M$-10.60M$22.26M
Low Forecast$-184.03M$-144.64M$-116.13M$-34.18M$-49.97M$-32.87M$-27.02M$-10.60M$22.26M
Surprise %-57.81%-36.77%-53.99%-166.73%40.65%----

SPRO Forecast FAQ

Is Spero Therapeutics stock a buy?

Spero Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spero Therapeutics is a favorable investment for most analysts.

What is Spero Therapeutics's price target?

Spero Therapeutics's price target, set by 9 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.89.

How does Spero Therapeutics stock forecast compare to its benchmarks?

Spero Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Spero Therapeutics over the past three months?

  • June 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Spero Therapeutics’s EPS forecast?

Spero Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.58, marking a -54.33% decrease from the reported $-1.27 in 2024. Estimates for the following years are $-0.51 in 2026, $-0.2 in 2027, and $0.42 in 2028.

What is Spero Therapeutics’s revenue forecast?

Spero Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $30M, reflecting a -37.47% decrease from the reported $47.98M in 2024. The forecast for 2026 is $1.3M, followed by $32.5M for 2027, and $63M for 2028.

What is Spero Therapeutics’s net income forecast?

Spero Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-30.91M, representing a -54.92% decrease from the reported $-68.566M in 2024. Projections indicate $-27.024M in 2026, $-10.598M in 2027, and $22.26M in 2028.